{"result": {"id": "e7de139d-5f34-452c-9fa1-4037a8e7fb8d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "I notice the text is primarily a list of pharmaceutical drugs and their properties, which don't clearly fit the requested entity types (organization, person, geo, event). Since none of these drugs qualify as organizations, people, geographic locations, or events, and there are no clear relationships between them beyond being part of the same drug classification system, no additional entities or relationships meet the specified criteria.\n\nThe previous extraction correctly identified that no valid entities of the requested types exist in this pharmaceutical data. Therefore, no additional output needs to be added.\n\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558687, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 114, "prompt_tokens": 4491, "total_tokens": 4605, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4416}, "prompt_cache_hit_tokens": 4416, "prompt_cache_miss_tokens": 75}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 6~9\t　　　\t1\t\n缬沙坦\t9\t　　　\t1\t\n厄贝沙坦\t11~15\t　　　\t1\t\n替米沙坦\t24\t　　　\t1\t\n坎地沙坦酯\t9. 5~11. 2\t　　　\t1\t\n奥美沙坦酯\t13\t　　　\t1\t\n阿利沙坦酯\t10\t　　　\t1\t\n美阿沙坦钾\t11\t　　　\t1\t\n阿齐沙坦\t12. 8~13. 2\t　　　\t1\t\n\n\n续表 15\n\n口服降压药\t消除半衰期(h)\t剂量(起始剂量~足量)\n(mg/d)\t每天服药 次数\t主要不良反应\n噻嗪类利尿剂 氢氯噻嗪\n氯噻酮\n吲达帕胺\n吲达帕胺缓释片\t\n15\n　　35~50 18(14~24)\n-\t\n6. 25~25\n12. 5~25\n1. 25~2. 5 1. 5\t\n1\n1\n1\n1\t血钾降低 ,血钠降低 ,血尿酸升高\n袢利尿剂\t\t\t\t血钾减低\n呋塞米\t1, 肾功能受损 10以上 *\t20~80\t2~3\t\n托拉塞米\t3. 5,肾功能受损 4. 9\t5~10\t1\t\n保钾利尿剂 阿米洛利 氨苯蝶啶\t\n　6~9 1. 5~2\t\n　5~10   25~100\t\n1~2 2\t血钾增高\nβ受体阻滞剂\t\t\t\t支气管痉挛 ,心功能抑制\n非选择性\n普萘洛尔\t2~3\t20~90\t2~3\t\n选择性\n美托洛尔平片\t3~5\t50~100\t2\t\n美托洛尔缓释片\t以几乎恒定速度释放 ,约 20\t47. 5~190\t1\t\n比索洛尔\t10~12\t2. 5~10\t1\t\n阿替洛尔\t6~7\t12. 5~50\t1~2\t\n倍他洛尔\t16~20\t5~20\t1\t\nα、β受体阻滞剂\t\t\t\t体位性低血压 ,支气管痉挛\n拉贝洛尔\t6~8\t200~600\t2\t\n卡维地洛\t6~10\t12. 5~50\t2\t\n阿罗洛尔\t10\t10~30\t1~2\t\n贝凡洛尔\t约 10\t100~200\t2\t\n血管紧张素受体脑啡肽酶抑制剂 沙库巴曲缬沙坦钠\n沙库巴曲阿利沙坦钙\t\n11. 5/9. 9 11. 5/10\t\n200~400 240~480\t\n1\n1\t低血压、高钾血症、血管神经性水肿(极少见)\nα受体阻滞剂\t\t\t\t体位性低血压\n多沙唑嗪\t22\t0. 5~8\t1\t\n多沙唑嗪缓释片\t\t1~16\t1\t\n哌唑嗪\t2~3\t1~10\t2~3\t\n特拉唑嗪\t12\t1~20\t1~2\t\n盐皮质激素受体拮抗剂\t\t\t\t\n螺内酯\t19(12~25)\t20~60\t1~3\t血钾增高 ,男性乳房发育\n依普利酮\t4~6\t25~100\t1~2\t血钾增高\n非奈利酮\t2~3\t10~20\t1\t血钾增高\n直接肾素抑制剂\t\t\t\t腹泻、高血钾\n阿利吉仑\t40(34~41)\t150~300\t1\t\n中枢作用药物\t\t\t\t\n利血平\t45~168\t0. 125~0. 5\t1~2\t鼻充血 ,心动过缓 ,消化性\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>缬沙坦<|>organization<|>An oral antihypertensive drug with an elimination half-life of 9 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>厄贝沙坦<|>organization<|>An oral antihypertensive drug with an elimination half-life of 11-15 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>替米沙坦<|>organization<|>An oral antihypertensive drug with an elimination half-life of 24 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>坎地沙坦酯<|>organization<|>An oral antihypertensive drug with an elimination half-life of 9.5-11.2 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>奥美沙坦酯<|>organization<|>An oral antihypertensive drug with an elimination half-life of 13 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>阿利沙坦酯<|>organization<|>An oral antihypertensive drug with an elimination half-life of 10 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>美阿沙坦钾<|>organization<|>An oral antihypertensive drug with an elimination half-life of 11 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>阿齐沙坦<|>organization<|>An oral antihypertensive drug with an elimination half-life of 12.8-13.2 hours and a daily dosage range of 1 mg/d)\n##\n(\"entity\"<|>氢氯噻嗪<|>organization<|>A thiazide diuretic with an elimination half-life of 15 hours and a daily dosage range of 6.25-25 mg/d)\n##\n(\"entity\"<|>氯噻酮<|>organization<|>A thiazide diuretic with an elimination half-life of 35-50 hours and a daily dosage range of 12.5-25 mg/d)\n##\n(\"entity\"<|>吲达帕胺<|>organization<|>A thiazide diuretic with an elimination half-life of 18 hours and a daily dosage range of 1.25-2.5 mg/d)\n##\n(\"entity\"<|>吲达帕胺缓释片<|>organization<|>A thiazide diuretic with an elimination half-life of 14-24 hours and a daily dosage range of 1.5 mg/d)\n##\n(\"entity\"<|>呋塞米<|>organization<|>A loop diuretic with an elimination half-life of 1 hour (10+ in renal impairment) and a daily dosage range of 20-80 mg/d)\n##\n(\"entity\"<|>托拉塞米<|>organization<|>A loop diuretic with an elimination half-life of 3.5 hours (4.9 in renal impairment) and a daily dosage range of 5-10 mg/d)\n##\n(\"entity\"<|>阿米洛利<|>organization<|>A potassium-sparing diuretic with an elimination half-life of 6-9 hours and a daily dosage range of 5-10 mg/d)\n##\n(\"entity\"<|>氨苯蝶啶<|>organization<|>A potassium-sparing diuretic with an elimination half-life of 1.5-2 hours and a daily dosage range of 25-100 mg/d)\n##\n(\"entity\"<|>普萘洛尔<|>organization<|>A non-selective beta-blocker with an elimination half-life of 2-3 hours and a daily dosage range of 20-90 mg/d)\n##\n(\"entity\"<|>美托洛尔平片<|>organization<|>A selective beta-blocker with an elimination half-life of 3-5 hours and a daily dosage range of 50-100 mg/d)\n##\n(\"entity\"<|>美托洛尔缓释片<|>organization<|>A selective beta-blocker with a constant release rate over 20 hours and a daily dosage range of 47.5-190 mg/d)\n##\n(\"entity\"<|>比索洛尔<|>organization<|>A selective beta-blocker with an elimination half-life of 10-12 hours and a daily dosage range of 2.5-10 mg/d)\n##\n(\"entity\"<|>阿替洛尔<|>organization<|>A selective beta-blocker with an elimination half-life of 6-7 hours and a daily dosage range of 12.5-50 mg/d)\n##\n(\"entity\"<|>倍他洛尔<|>organization<|>A selective beta-blocker with an elimination half-life of 16-20 hours and a daily dosage range of 5-20 mg/d)\n##\n(\"entity\"<|>拉贝洛尔<|>organization<|>An alpha and beta-blocker with an elimination half-life of 6-8 hours and a daily dosage range of 200-600 mg/d)\n##\n(\"entity\"<|>卡维地洛<|>organization<|>An alpha and beta-blocker with an elimination half-life of 6-10 hours and a daily dosage range of 12.5-50 mg/d)\n##\n(\"entity\"<|>阿罗洛尔<|>organization<|>An alpha and beta-blocker with an elimination half-life of 10 hours and a daily dosage range of 10-30 mg/d)\n##\n(\"entity\"<|>贝凡洛尔<|>organization<|>An alpha and beta-blocker with an elimination half-life of about 10 hours and a daily dosage range of 100-200 mg/d)\n##\n(\"entity\"<|>沙库巴曲缬沙坦钠<|>organization<|>An angiotensin receptor neprilysin inhibitor with an elimination half-life of 11.5/9.9 hours and a daily dosage range of 200-400 mg/d)\n##\n(\"entity\"<|>沙库巴曲阿利沙坦钙<|>organization<|>An angiotensin receptor neprilysin inhibitor with an elimination half-life of 11.5/10 hours and a daily dosage range of 240-480 mg/d)\n##\n(\"entity\"<|>多沙唑嗪<|>organization<|>An alpha-blocker with an elimination half-life of 22 hours and a daily dosage range of 0.5-8 mg/d)\n##\n(\"entity\"<|>多沙唑嗪缓释片<|>organization<|>An alpha-blocker with a daily dosage range of 1-16 mg/d)\n##\n(\"entity\"<|>哌唑嗪<|>organization<|>An alpha-blocker with an elimination half-life of 2-3 hours and a daily dosage range of 1-10 mg/d)\n##\n(\"entity\"<|>特拉唑嗪<|>organization<|>An alpha-blocker with an elimination half-life of 12 hours and a daily dosage range of 1-20 mg/d)\n##\n(\"entity\"<|>螺内酯<|>organization<|>A mineralocorticoid receptor antagonist with an elimination half-life of 19 hours and a daily dosage range of 20-60 mg/d)\n##\n(\"entity\"<|>依普利酮<|>organization<|>A mineralocorticoid receptor antagonist with an elimination half-life of 4-6 hours and a daily dosage range of 25-100 mg/d)\n##\n(\"entity\"<|>非奈利酮<|>organization<|>A mineralocorticoid receptor antagonist with an elimination half-life of 2-3 hours and a daily dosage range of 10-20 mg/d)\n##\n(\"entity\"<|>阿利吉仑<|>organization<|>A direct renin inhibitor with an elimination half-life of 40 hours and a daily dosage range of 150-300 mg/d)\n##\n(\"entity\"<|>利血平<|>organization<|>A centrally acting drug with an elimination half-life of 45-168 hours and a daily dosage range of 0.125-0.5 mg/d)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_6b20ef215d0b4322f2916fabe7f3ef10215ab0d49b992eca18915cd70d1fbe4f_v2"}